This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ardavanis, A. Articles by Rigatos, G. Search for Related Content PubMed PubMed Citation Articles by Ardavanis, A. Articles by Rigatos, G.

Breast Cancer

Trastuzumab plus Paclitaxel or Docetaxel in HER-2–Negative/HER-2 ECD–Positive Anthracycline- and Taxane-Refractory Advanced Breast Cancer

^aFirst Department of Medical Oncology and ^bNuclear Medicine Department, Saint Savas Oncology Hospital, Athens, Greece; ^cBiology Department, University of Athens, Athens, Greece

Key Words. HER-2/neu • HER-2 ECD • Metastatic breast cancer • Anthracycline/taxane resistant • Salvage

Correspondence: Alexandros Ardavanis, M.D., Saint Savas Oncology Hospital, 171 Alexandras Avenue, 115 22 Athens, Hellas. Telephone: 30-694-4421525 (mobile); Fax: 30-210-6409508; e-mail: ardavanis{at}yahoo.com

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Trastuzumab is considered effective against human epidermal growth factor receptor (HER)-2–positive breast cancer as assessed by immunohistochemistry (IHC) and fluorescence or chromogenic in situ hybridization (FISH/CISH) on biopsy material. Trastuzumab is now approved in both the adjuvant and metastatic settings for this patient population. Because HER-2 extracellular domain (ECD) levels have been correlated with disease progression in the metastatic setting, we considered trastuzumab salvage therapy plus a taxane in heavily pretreated trastuzumab-naive relapsed breast cancer patients with high serum levels of HER-2 ECD (15 ng/ml). All patients had previously failed at least two lines of anthracycline- and taxane-based regimens and were HER-2 negative by IHC and FISH/CISH prior to a centralized reanalysis, and were serum positive for HER-2 ECD (15 ng/ml) at baseline. Regular serum accounts of HER-2 ECD were recorded and compared with response and survival outcomes. Twenty-two patients were finally eligible for salvage therapy. Minor responses were observed in five (23%) and stable disease (SD) was observed in 11 patients, leading to a clinical benefit rate of 73% (16 of 22 patients). The median time to progression and overall survival time were 5 (6.5 months in minor responders and SD) and 12 months, respectively; 11 and eight patients remained progression free for >6 and >12 months, respectively. Eleven and seven patients were alive at 12 and 15 months, respectively, after treatment start. Furthermore, in total, 13 (59.1%) patients obtained a biochemical response. In our study, patients with conventionally HER-2–negative disease but with expression of HER-2 ECD above the normal limit (15 ng/ml) displayed a rapid response, both biochemically and clinically, to the trastuzumab–taxane combination. This is the first study assessing anti-HER-2–based treatment in HER-2–negative advanced breast cancer according to HER-2 ECD positivity; if our results are confirmed, additional patients with "hidden" HER-2–positive breast cancer might benefit from anti-HER-2 treatment.

This article has been cited by other articles:

				F. J. Esteva Commentary: Can Circulating HER-2 Extracellular Domain Predict Response to Trastuzumab in HER-2-Negative Breast Cancer? Oncologist, April 1, 2008; 13(4): 370 - 372. [Full Text] [PDF]